Drug and xenobiotic biotransformation in the blood–brain barrier: a neglected issue

José A. G. Agúndez1,2,*, Félix J. Jiménez-Jiménez 3, Hortensia Alonso-Navarro3 and Elena García-Martín2,4

1 Department of Pharmacology, University of Extremadura, Cáceres, Spain
2 ISCIII Research Network of Adverse Reactions to Allergens and Drugs, Madrid, Spain
3 Section of Neurology, Hospital Universitario del Sureste, Madrid, Spain
4 Department of Biochemistry, Molecular Biology and Genetics, University of Extremadura, Cáceres, Spain

Drug biotransformation is a crucial mechanism for facilitating the elimination of chemicals from the organism and for decreasing their pharmacological activity. Published evidence suggests that brain drug metabolism may play a role in the development of adverse drug reactions and in the clinical response to drugs and xenobiotics. The blood–brain barrier (BBB) has been regarded mainly as a physical barrier for drugs and xenobiotics, and little attention has been paid to the BBB as a drug-metabolizing barrier. The presence of drug-metabolizing enzymes in the BBB is likely to have functional implications because local metabolism may inactivate drugs or may modify the drug’s ability to cross the BBB, thus modifying drug response and the risk of developing adverse drug reactions. In this perspective paper, we discuss the expression of relevant xenobiotic metabolizing enzymes in the brain and in the BBB, and we cover current advances and future directions on the potential role of these BBB-drug-metabolizing enzymes as modifiers of drug response.

Keywords: blood–brain barrier, drug metabolizing enzymes, expression profiling, CNS drug, drug response

The concept of the blood–brain barrier (BBB) was developed over a century ago, when Ehrlich observed that dyes administered intravenously do not stain the brain. Goldmann refuted the so-called “binding hypothesis” (Goldmann, 1913) and established that the central nervous system (CNS) is separated from the bloodstream by the blood–brain and cerebro-spinal fluid (CSF) barriers. At present, most of the research related to the BBB has focused on how selected molecules, drugs, metabolites, and toxic substances are able to enter and leave the brain (for a recent review, see Pardridge, 2012). In fact, the BBB has been traditionally regarded as a physical barrier that protects the CNS from non-lipophilic drugs and xenobiotics. In contrast, the putative role of the BBB as a drug-metabolizing barrier has received little attention. The presence of drug-inactivating enzymes in the BBB is likely to affect drug response, as does the presence of such enzymes in the intestine and liver (Pereira de Sousa and Bernkop-Schnurch, 2014). Local metabolism may modify the response and the risk of developing adverse drug reactions with drugs affecting the CNS, and the presence of drug-inactivating enzymes in the BBB may constitute an additional protecting mechanism against drugs and xenobiotics, which may act regardless of their lipophilicity.

With the obvious quantitative differences in enzyme expression of drug-inactivating enzymes between the BBB and the functional unit responsible for pre-systemic metabolism (intestinal enzymes (Pereira de Sousa and Bernkop-Schnurch, 2014), gut microbiota (Kang et al., 2013), and first pass in the liver), drug inactivation in the BBB may constitute a relevant quantitative or qualitative factor for CNS drugs, if these are metabolized by enzymes expressed in the BBB. In fact, a relevant problem in the study of drug response, with regard to drugs affecting the CNS, is related to large interspecies differences in drug bioavailability and distribution within the CNS, including differences between primates and humans; these differences, which would not be expected in a purely physical barrier, are likely to be related to differences in the BBB function. Regarding CNS drugs, this variability could be the consequence of variation in the expression patterns and function of drug-metabolizing enzymes and transporters in the BBB. Of great interest is the development of in vitro BBB models using brain vascular endothelial cell cultures which permit the characterization and quantification of genes and proteins in brain microvessels from different species (Shawahna et al., 2013). This methodological advance, together with in vivo studies comparing drug concentration and metabolic profiles on both sides of the BBB, will contribute in coming years to greater knowledge of the metabolic and functional implications of the BBB.

ENZYMES THAT METABOLIZE CNS DRUGS

The BBB expresses a variety of neurotransmitter-metabolizing enzymes such as monoamine oxidases (MAO), catechol-O-methyl transferase (COMT), cholinesterases, GABA transaminase, aminopeptidases, and endopeptidases. Several drug- and xenobiotic-detoxicating enzymes are found in brain capillaries (Minn et al., 1991; de Leon, 2003; Granberg et al., 2003; Haseloff et al., 2006; Ueno, 2009; Wang et al., 2011), thus constituting an enzymatic mechanism that protects the brain from circulating neurotransmitters and from drugs and toxins. For many CNS drugs, metabolic predispositions are a crucial mechanism in determining drug effects. Among the enzymes involved in drug metabolism, two main enzyme categories (Phase I and Phase II) exist. The most relevant Phase I enzymes, in terms of

Frontiers in Cellular Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 335 | 1
percentage of drugs that they metabolize, are the cytochrome P450 (CYP) CYP3A (including CYP3A4 and CYP3A5, which share several substrates), CYP2D6, CYP2C9 [which share several substrates with CYP2C8, particularly non-steroidal anti-inflammatory drugs (Agúndez et al., 2009)], CYP1A1/1A2 and, to a lesser extent, CYP2C19, CYP2E1, CYP1B1, and other CYP enzymes (Evans and Relling, 1999). Regarding Phase II enzymes, the most relevant in terms of percentage of drugs metabolized are UDP-glucuronosyltransferases (UDPs), glutathione S-transferases (GSTs), sulfotransferases (SULTs), and N-acetyltransferases (NATs) particularly NAT2 (Evans and Relling, 1999). Drugs belonging to many pharmacological groups are affected by polymorphic metabolism mediated by these enzymes, including for instance anesthetics, anti-Parkinson’s disease drugs, antihistamine drugs, antipsychotics, narcotics, or antidepressants; specific recommendations for the use of these drugs in the context of variability in drug metabolism have been published (Restrepo et al., 2009; Khokhar and Tyndale, 2011; Swen et al., 2011; Agúndez et al., 2013; Garcia-Martin et al., 2013).

DRUG-METABOLIZING ENZYMES IN THE BRAIN

Most available information on the expression of drug-metabolizing enzymes in the CNS corresponds to the whole brain. The expression of CYP450 in the whole brain was reported by Nishimura et al. (2003). Dutheil et al. (2009) showed the apparent selective expression in several cerebral regions in both neuronal and glial cells. The most relevant enzymes were CYP1B1, CYP2D6, CYP2E1, CYP2J2, CYP2U1, and CYP46A1, with heterogeneous distribution in different brain areas (Dutheil et al., 2009). Tissue-specific features are becoming apparent from recent studies. For instance, the dura-mater is clearly different from the other brain structures because of its particular pattern expression of CYP450, with a high level of CYP1B1 and, to a lesser extent CYP1A1, CYP2U1, CYP3A5, CYP2R1, CYP2E1, CYP2D6, and CYP46A1 (Dutheil et al., 2009). The European Bioinformatics Institute Expression Atlas1 (available at the website), provides interesting information on the baseline expression of drug-metabolizing enzymes in the human brain. When comparing the expression in the brain and in the liver, what is striking is how the brain is almost entirely the CNS, including the CNS when entering the CNS. An exhaustive list of drugs and substrates of drug-metabolizing enzymes present in the BBB falls beyond the scope of a perspective article, but some examples are the following: CYP1B1 metabolizes, among other substrates, amiodarone, caffeine, theophylline, melatonin, and procarbazine (Shimada et al., 1997, 1999; Li et al., 2000, 2002; Spink et al., 2000; Bournique and Lemarie, 2002; Patterson and Murray, 2002; Choudhary et al., 2004; Dubey et al., 2005; Ma et al., 2005; Zhang et al., 2007), CYP46A1 participates in the metabolism of analgesics such as dextromethorphan, diclofenac, or phenacetin (Mast et al., 2003); CYP2D6 participates in the metabolism of several antidepressive agents, antipsychotics, and other CNS drugs (for a recent review, see Agúndez and García-Martin, 2014). CYP2J2 metabolizes ergocalciferol, ebastine, and astemizole (Hashizume et al., 2002; Matsumoto et al., 2002, 2003; Lee et al., 2005; Zhou et al., 2005; Aiba et al., 2006). CYP2E1 participates in the metabolism of anesthetics and ethanol (Zakhari, 2006; Restrepo et al., 2009; Martinez et al., 2010). CYP2R1 participates in the metabolism of ergocalciferol and colecalciferol (Schuster, 2011). HNMT metabolizes histamine, particularly in the CNS, and HNMT gene

1 http://www.ebi.ac.uk/gxa/home
variations are relatively common and affect the enzyme activity (Garcia-Martin et al., 2009). GST enzymes in the BBB impair accumulation and cause therapeutic failure for antiepileptic drugs (Shang et al., 2008).

CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES

In contrast to the extensive investigation of drug-metabolizing enzymes in the human liver carried out in the last three decades, and compared to the present knowledge of drug transporters in the BBB, the implications of drug-metabolizing enzymes in the BBB are poorly understood. These enzymes may be a major cause of dissociation between the drug concentrations observed in the CSF and plasma, and may underlie therapeutic failure, even when plasma drug concentrations are optimal. Several issues that require further investigation include the following:

(1) Identification and quantification of all drug-metabolizing enzymes in the BBB. So far our knowledge is very limited and further studies are required to identify more enzymes, to analyze their expressions in different structures in the BBB, and to study the interindividual variability in the expression of these enzymes.

(2) Specific characteristics of the drug-metabolizing enzymes expressed in the BBB. The first exhaustive gene profiling of P450 in human brain microvessels was carried out by Dauchy et al. (2008). According to the 1000 genomes catalog2 (available at the website), most of these enzymes show several splice variants. For example, CYP1B1 has seven transcripts, two of which encode full-length protein, CYP2U1 has three transcripts, two of these with protein product, GSTP1 has nine transcripts, GSTM has fourteen, GSTM3 and GSTM5 have six each, and GSTO1 has seven. With the exception of CYP2D6, which has only one known transcript, the enzymes detected in the BBB at mRNA level also have several transcripts: CYP2J2 has five transcripts (although only one functional), CYP2E1 and CYP2R1 have ten transcripts each. It is crucial to know which transcripts are expressed in the BBB, both under basal conditions and in CNS or vascular disorders, as well as their characteristics (substrate specificity, Vmax, or Km).

(3) Mechanisms involved in the regulation and functional effects of drug-metabolizing enzymes in the BBB: Effects of known inducers of liver enzymes on BBB drug-metabolizing enzymes, the effect of gene variations, and factors underlying the interindividual variability in enzyme activity.

(4) Effects of known inhibitors of the liver enzymes on the BBB enzymes. This is a crucial factor that may underlie drug interactions which cannot be assessed by conventional therapeutic drug monitoring, that is, by determination of drug concentration in plasma.

In summary, besides acting as a physical barrier, the BBB constitutes a highly specialized metabolic barrier, and contains several drug-metabolizing enzymes, many of which have the ability to inactivate drugs and toxins before they enter the CNS. According to the specific pattern of enzymes, the BBB metabolic barrier has a different metabolic profile than that of pre-systemic metabolism, where CYP3A4 and CYP3A5 enzymes play a key role. These CYP3A enzymes, which show little selectivity since they are involved in the metabolism of a high percentage of clinically used drugs (Evans and Relling, 1999), are not present in the BBB (Shawahna et al., 2011). The metabolic BBB barrier seems to be selective for specific types of drugs or xenobiotics that are metabolized by the enzymes present in the BBB. Nevertheless, much additional information is necessary to gain more ground in BBB metabolism and it is expected that in the coming years we will have new information available for assessing the potential and clinical implications of local drug metabolism in the BBB, which so far have received little attention.

ACKNOWLEDGMENTS

We are grateful to Prof. James McCue for assistance in language editing. The work in the author’s laboratory is financed by Grants PI12/00241, PI12/00324, and RETICS RD12/0013/0002, and by Grants GR10068 from Junta de Extremadura, Spain. Financed in part with FEDER funds from the European Union.

REFERENCES

Agündez, J. A., and García-Martin, E. (2014). “Importance of CYP2D6 genotype/activity testing and applications,” in CYP2D6: Genetics, Pharmacology and Clinical Relevance, ed. P. Baumann (London: Future Medicine Ltd.), 118–133.

Agündez, J. A., Garcia-Martin, E., Alonso-Navarro, H., and Jimenez-Jimenez, F. J. (2013). Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin. Drug Metab. Toxicol. 9, 859–874.

Agündez, J. A., Garcia-Martin, E., and Martinez, C. (2009). Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5, 607–620.

Aiba, I., Yamasaki, T., Shinkti, T., Izumi, S., Yamamoto, K., Yamada, S., et al. (2006). Characterization of rat and human CYP2J enzymes as vitamin D 25-hydroxylases. Steroids 71, 849–856.

Bourguin, B., and Lemarie, A. (2002). Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 30, 1149–1152.

Choudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M., and Schenkerman, J. B. (2004). Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. 32, 840–847.

Dauchy, S., Dutheil, F., Weaver, R. J., Chassoux, F., Daumas-Dupont, C., Couraud, P. O., et al. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107, 1518–1528.

Declèves, X., Jacob, A., Yousif, S., Shawahna, R., Potin, S., and Scherrmann, J. M. (2011). Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr. Drug Metab. 12, 732–741.

de Leon, J. (2003). Glucuronidation enzymes, genes and psychiatry. Int. J. Neuropsychopharmacol. 6, 57–72.

Dubey, R. K., Jackson, E. K., Gillespie, D. G., Rosselli, M., Barchiesi, F., Krust, A., et al. (2005). Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J. Clin. Endocrinol. Metab. 90, 247–255.

Dutheil, F., Dauchy, S., Dirty, M., Szabovitch, V., Cloarec, O., Mellotte, L., et al. (2009). Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. 37, 1528–1538.

Evans, W. E., and Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491.

García-Martin, E., Ayuso, P., Martinez, C., Blanca, M., and Agundez, J. A. (2009). Histamine pharmacogenomics. Pharmacogenomics 10, 867–883.

2http://browser.1000genomes.org/Homo_sapiens/Search/New?db=core
Garcia-Martín, E., Canto, G., and Agundez, J. A. (2013). Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opin. Drug Metab. Toxicol. 9, 1437–1452.

Goldmann, E. E. (1913). “Vitalfärbung am zentralnervensystem: Beitrag zur Physio-Pathologie des Plexus Chorioideus und der Hirnhäute,” in Abhandlungen Preussischen Akademie der Wissenschaften Physikalisch Mathematischer klasse, Vol. 1 (Berlin: Königl. Akademie der Wissenschaften), 1–60.

Granberg, L., Ostergren, A., Brandt, I., and Brittebo, E. B. (2003). CYPIA1 and CYPIB1 in blood-brain interfaces: CYPIA1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells. Drug Metab. Dispos. 31, 259–265.

Haseloff, R. F., Krause, E., Bigl, M., Mikotiet, K., Staniimirovic, D., and Blasié, J. I. (2006). Differential protein expression in brain capillary endothelial cells induced by hypoxia and posthypoxic reoxygenation. Proteomics 6, 1803–1809.

Hashizume, T., Imaoaka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., et al. (2002). Involvement of CYPI2J and CYPI4F12 in the metabolism of estriol in human intestinal microsomes. J. Pharm. Exp. Ther. 300, 298–304.

Kang, M. I., Kim, H. G., Kim, J. S., Oh do, G., Um, Y. J., Seo, C. S., et al. (2013). The effect of gut microbiota on drug metabolism. Expert Opin. Drug Metab. Toxicol. 9, 1295–1308.

Khokhar, J. Y., and Tyndale, R. F. (2011). Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropharmacology 56, 692–700.

Lee, S. S., Jeong, H. E., Liu, K. H., Ryu, I. Y., Moon, T., Yoon, C. N., et al. (2005). Identification and functional characterization of novel CYPI2J variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet. Genomics 15, 105–113.

Li, D. N., Seidel, A., Pritchard, M. P., Wolf, C. R., and Friedberg, T. (2000). Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially cancerous metabolite 4-hydroxyestradiol. Pharmacogenetics 10, 343–353.

Li, X. Q., Bjorkman, A., Andersson, T., Rivderstrom, M., and Masimirembwa, C. M. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300, 399–407.

Ma, X., Ildie, J. R., Krausz, K. W., and Gonzalez, F. J. (2005). Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos. 33, 489–494.

Martinez, C., Galvan, S., Garcia-Martin, E., Ramos, M. I., Gutierrez-Martin, Y., and Agundez, J. A. (2010). Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. Hepatology 51, 491–500.

Mast, N., Norcross, R., Andersson, U., Shou, M., Nakayama, K., Bjorkhem, I., et al. (2003). Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry 42, 14284–14292.

Matsumoto, S., Hirama, T., Kim, H. J., Nagata, K., and Yamazoe, Y. (2003). In vitro inhibition of human small intestinal and liver microsomal amidomethyl-O-demethylase: different contribution of CYP1J2 in the small intestine and liver. Xenobiotica 33, 615–623.

Matsumoto, S., Hirama, T., Matsubara, T., Nagata, K., and Yamazoe, Y. (2002). Involvement of CYPI2J on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos. 30, 1240–1245.

Minn, A., Ghersi-Egea, J. I., Perrin, R., Leininger, B., and Siest, G. (1991). Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res. Brain Res. Rev. 16, 65–82.

Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S., and Satoh, T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123, 369–375.

Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959–1972.

Patterson, L. H., and Murray, G. I. (2002). Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8, 1335–1347.

Pereira de Sousa, I., and Bernkop-Schnurch, A. (2014). Pre-systemic metabolism of orally administered drugs and strategies to overcome it. J. Control. Release 192C, 301–309.